Mutational inactivation of ATRX (α-thalassemia mental retardation X-linked) represents a defining molecular alteration in large subsets of malignant glioma. Yet the pathogenic consequences of ATRX deficiency remain unclear, as do tractable mechanisms for its therapeutic targeting. Here we report that ATRX loss in isogenic glioma model systems induces replication stress and DNA damage by way of G-quadruplex (G4) DNA secondary structure. Moreover, these effects are associated with the acquisition of disease-relevant copy number alterations over time. We then demonstrate, both in vitro and in vivo, that ATRX deficiency selectively enhances DNA damage and cell death following chemical G4 stabilization. Finally, we show that G4 stabilization synergizes with other DNA-damaging therapies, including ionizing radiation, in the ATRX-deficient context. Our findings reveal novel pathogenic mechanisms driven by ATRX deficiency in glioma, while also pointing to tangible strategies for drug development.
I nfiltrating gliomas are the most common primary brain tumors and, despite considerable molecular and clinical heterogeneity, remain uniformly deadly in the face of aggressive surgical and cytotoxic treatment regimens 1 . Recent large-scale genomic profiling has shown that inactivating mutations in ATRX (α-thalassemia mental retardation X-linked) characterize large subclasses of both adult and pediatric glioma [2] [3] [4] . Despite these striking correlations, however, the precise mechanisms by which ATRX mutation promotes gliomagenesis remain unclear. Recent reports have linked germline ATRX mutations to osteosarcoma [5] [6] [7] , and their association with a rare, congenital neurodevelopmental condition (ATR-X syndrome) is well-established 8 . ATRX encodes a chromatin binding protein widely implicated in epigenetic regulation and remodeling [9] [10] [11] [12] [13] [14] [15] , suggesting that epigenomic dysfunction may, at least in part, underlie the oncogenic effects of ATRX deficiency. ATRX loss has also been implicated in alternative lengthening of telomeres (ALT), an abnormal telomerase-independent mechanism of telomere maintenance based on homologous recombination 16, 17 . Finally, ATRX deficiency has been repeatedly linked to replication stress, DNA damage, copy number alterations (CNAs), and aneuploidy [18] [19] [20] [21] [22] [23] , and recent work has associated ATRX deficiency specifically with copy number loss at ribosomal DNA loci 24 . Whether and how such genomic instability contributes to the initiation and/or evolution of malignant glioma remains unclear.
ATRX binds widely across the genome at sites featuring tandem repeats and CpG islands 25 . Many such loci are GC-rich and susceptible to forming G-quadruplexes (G4s), abnormal secondary structures implicated in both transcriptional dysregulation and DNA damage. Accordingly, it has been hypothesized that, among its various functionalities, ATRX serves to resolve G4s genome-wide and mitigate their deleterious consequences 25, 26 . The tendency of G4s to stall replication forks underlies their association with DNA damage 27 . Chemical stabilization of G4s induces replication stress at genomic loci prone to G4 formation 28 , and also promotes DNA damage and apoptosis in neural progenitor cells 29 . Moreover, recent work suggests that G4-induced replication stress at telomeres may drive ALT in the ATRX-deficient setting through induction of homologous recombination 16 . Indeed, G4 stabilization hampers the ability of forced ATRX expression to abrogate the ALT phenotype in vitro. Taken together, these findings provide compelling links between ATRX, G4 biology, and genomic instability. Whether ATRX deficiency directly induces G4 formation and DNA damage, however, remains unestablished, as does the impact of G4s on the pathogenesis of ATRX-deficient neoplasia. Moreover, therapeutic strategies leveraging G4 biology in the selective targeting of ATRX-deficient cancers have not been extensively explored.
To characterize the role of G4-mediated genomic instability in glioma biology, we inactivated ATRX in isogenic normal human astrocyte (NHA) and glioma stem cell (GSC) models. We found that ATRX loss increased G4 formation, replication stress, and DNA damage genome-wide. Moreover, ATRX-deficient NHAs accumulated clinically relevant CNAs at an accelerated rate relative to ATRX-intact counterparts. Chemical G4 stabilization was associated with enhanced DNA damage and cell death in ATRX-deficient contexts. Moreover, ATRX-mutant GSC xenografts were selectively sensitive to G4-targeting in vivo. Finally, G4 stabilization in ATRX-deficient NHAs and GSCs effectively synergized with other DNA-damaging treatment strategies, including ionizing radiation. These findings clarify distinct mechanisms by which G4s influence ATRX-deficient glioma pathogenesis and indicate that G4 stabilization may represent an attractive therapeutic strategy for the selective targeting of ATRX-mutant cancers.
Results
ATRX deficiency promotes G4 formation and DNA damage. To model the genomic consequences of ATRX deficiency in a glioma-relevant cellular context, we performed shRNA-mediated ATRX knockdown in TERT and E6/E7-transformed NHAs. Several studies have effectively employed immortalized NHAs to delineate key aspects of glioma biology [30] [31] [32] [33] [34] . In our investigations, we employed two distinct hairpin constructs to silence ATRX-shATRX1 and shATRX2-the latter of which was driven by a doxycycline (dox)-inducible promoter (Fig. 1a ). This framework allowed for the analysis of both immediate and long-term effects of ATRX deficiency as well as their reversibility. Using a monoclonal antibody known to recognize G4 structures in situ (1H6), we then demonstrated that ATRX deficiency increased nuclear G4s relative to levels seen in control shRNA-expressing parental NHAs (shCon), an effect that was reversible upon restored ATRX expression ( Fig. 1b-c) . Increased G4s were also found in p53-deficient murine neuroepithelial progenitor cells (mNPCs) featuring inactivated Atrx ( Supplementary Fig. 1a ).
The specificity of 1H6 for DNA-based secondary structures was confirmed by DNAase treatment, which eradicated immunolabelling, and RNase treatment, which did not, in NHAs treated with the G4-stabilizing agent CX-3543 (see below, Supplementary Fig. 1b ). Moreover, the effects of ATRX knockdown on nuclear G4 levels in isogenic NHAs, as assessed by 1H6 immunofluorescence, were recapitulated with a different G4-targeting monoclonal antibody (BG4; Supplementary Fig. 1c ). Forced expression of the isocitrate dehydrogenase 1 (IDH1) R132H mutation in our isogenic NHAs did not significantly alter G4 levels (as assessed by BG4) in either the ATRX-intact or the ATRX-deficient context ( Supplementary Fig. 1d ). ATRX deficiency almost invariably co-occurs with mutations in IDH1 or its homologue IDH2 in adult gliomas. We also compared GSCs derived from IDH-mutant, ATRX-mutant (08-0537) and IDHmutant, ATRX wild-type (TS 603) gliomas, finding increased nuclear G4s in the former by BG4 immunofluorescence (Fig. 1d ). Finally, we found that ATRX knockdown (sh590) in a glioblastoma-derived GSC (TS 543; IDH and ATRX wild type) enhanced G4 formation ( Fig. 1e and Supplementary Fig. 1e ). These data show that, in multiple glioma-relevant cellular contexts, ATRX deficiency promotes G4 accumulation.
To further support these findings, we employed a synthetic single-chain antibody (hf2) to immunoprecipitate G4s in both ATRX-intact and ATRX-deficient contexts. hf2 specificity was validated by gel-shift assay showing specific capture of synthesized Kit2 nucleotides independently from random ssDNA and dsDNA ( Supplementary Fig. 2a ). We then performed pulldowns in our isogenic NHAs, finding that ATRX deficiency significantly increased the qPCR enrichment of known G4 sites within the MYC and ZNF618 loci, as well as in telomeric regions on chromosomes 1, 2, and X ( Fig. 1f ) [35] [36] [37] . Consistent with the notion that ATRX resolves G4s as part of its normal functionality, we found a distinct absence of colocalization between ATRX and G4 immunofluorescence in ATRX-intact NHAs (Fig. 1g) . Finally, functional studies demonstrated that ATRX knockdown failed to induce significant changes in apoptosis, BrdU incorporation, or cell cycle profile ( Supplementary Fig. 2b-d ). Taken together, these findings confirm, in a true isogenic system, that ATRX deficiency promotes G4 formation. Moreover, they indicate that, at least in this glioma-relevant context, increased G4s as a consequence of ATRX deficiency are insufficient to drive apoptosis or impact cellular proliferation.
We then examined whether the G4s induced by ATRX deficiency promoted replication stress and DNA damage, as suggested by prior literature 38 . We found that ATRX knockdown significantly and reversibly increased γ-H2AX and 53BP1-positive DNA damage foci by immunofluorescence ( Fig. 2a -c), and did so in a pattern that extensively colocalized with nuclear G4 distribution, as assessed by both 1H6 and BG4 ( Fig. 2c and Supplementary Fig. 3 ). Moreover, these changes were accompanied by engagement of the replication stress pathway, as evidenced by upregulated levels p-CHK1 and p-KAP1 on western blot ( Fig. 2d ). To further ascertain the extent of colocalization between G4s and DNA damage sites in the ATRX-deficient context, we performed chromatin immunoprecipitation (ChIP) for γ-H2AX and Bloom syndrome RecQ-like helicase (BLM), a protein known to bind G4 DNA 39 . We found that ATRX loss significantly increased both γ-H2AX and BLM enrichment at putative G4 sites within the MYC and ZNF618 loci ( Fig. 2e ), far exceeding effects at a negative control locus (ESR1). To determine whether increased levels of DNA damage in the ATRX-deficient setting might lead to structural abnormalities in chromosomes, we performed metaphase cytogenetic analysis coupled with telomere-fluorescence in situ hybridization (FISH) in shCon and shATRX1 NHAs uniformly aged to 15 passages. Consistent with multiple prior reports, ATRX knockdown in this context was not associated with an obvious ALT phenotype ( Supplementary Fig. 4a, b ). However, we consistently observed higher levels of chromosome breakage in ATRX-deficient NHAs relative to shCon counterparts ( Fig. 3a and Supplementary  Fig. 4b ). Increased chromosome breaks were also observed in ATRX-mutant 08-0537 GSCs relative to ATRX wild-type TS 603 GSCs ( Fig. 3b and Supplementary Fig. 4c ), and a similar trend, though not statistically significant, was seen in p53-deficient mNPCs also featuring Atrx inactivation (versus p53-deficient, Atrx-intact isogenics; Fig. 3c and Supplementary Fig. 4d ). These data establish pathogenic links between G4s arising with ATRX deficiency and the generalized genomic instability characteristic of ATRX-mutant tumors and cell lines.
ATRX deficiency drives clinically relevant CNA formation.
Having confirmed that ATRX deficiency induces DNA damage and structural abnormalities in chromosomes, likely through G4-mediated mechanisms, we sought to assess whether these biological processes might promote acquisition of CNAs in ATRX-deficient tumors. ATRX mutations in adult glioma arise almost exclusively in the setting of concurrent mutations in TP53 and either IDH1 or IDH2. The glioma subtype defined by this combined genotype, termed "IDHmut-noncodel" 2 , features Moreover, multiple CNAs recurrently featured in ATRX-deficient glioma mobilize established oncogenic and/or tumor suppressive loci, including MYC and CDKN2A 2 , implying that such structural abnormalities may contribute to the malignant evolution of this inexorably progressive cancer.
To experimentally model CNA formation in the ATRXdeficient setting, we aged our isogenic NHAs in culture, monitoring DNA copy number by SNP array at 5 and 15 passages-~1 month and~3 months in culture, respectively ( Supplementary Fig. 5 ). We found that while both sets of isogenics demonstrated increased CNAs over time, ATRXdeficient NHAs exhibited a distinct pattern of gains and losses that included larger (>1 Mb) alterations not seen in ATRX-intact counterparts ( Fig. 4a ). Analysis of TCGA SNP data revealed a similar subset of broad alterations included within the CNA profile of the IDHmut-noncodel glioma subtype ( Fig. 4b ). Moreover, two of the broad CNAs arising with ATRX deficiency in NHAs, involving 12p gain and 14q loss, recapitulated events commonly seen in the IDHmut-noncodel glioma subtype and associated with relatively unfavorable prognosis when present ( Fig. 4c-f ). Taken together, these findings support the notion that G4-mediated DNA damage induces specific patterns of CNAs in the ATRX-deficient, IDHmut-noncodel glioma subtype, which in turn influence malignant evolution.
Chemical G4 stabilization selectively targets ATRX-deficient cells. As indicated above, the pronounced effects of ATRX deficiency on G4 formation and replication stress in NHAs were not associated with increased cell death at baseline. Nevertheless, we reasoned that compensatory mechanisms to resolve G4s and otherwise maintain genomic integrity were likely under increased stress, and that chemical stabilization of G4s might, therefore, selectively enhance DNA damage to an unsustainable degree in the ATRX-deficient context. To evaluate the therapeutic potential of this synthetic lethal approach, we treated our isogenic NHAs in culture with increasing concentrations of CX-3543 (Quarfloxin), an established G4-stabilizing agent 40, 41 . We found that ATRX knockdown, in both constitutive and inducible systems, was associated with increased sensitivity to CX-3543 (IC50 = 42.449 nM (shATRX1) vs 328.835 nM (shCon) in constitutive NHAs and IC50 = 357.424 nM (pre-induction) vs 53.415 nM (shATRX2) vs 247.700 nM (post-induction) in inducible NHAs; Fig. 5a , b). Similar results were obtained with twoother G4-stabilizing agents, pyridostatin (PDS) and CX-5461 ( Supplementary Fig. 6a -b) 28, 42 . Clonogenicity studies also revealed enhanced vulnerability to CX-3543 in ATRX-deficient NHAs as well as TS 543 GSCs subjected to ATRX knockdown (sh590; Fig. 5c, d ). Restoring ATRX expression reverted NHAs to baseline levels of sensitivity ( Fig. 5b) .
γ-H2AX immunofluorescence demonstrated dramatically increased levels of DNA damage in ATRX-deficient NHAs treated with CX-3543, accompanied by activation of the replication stress pathway as determined by western blot (Fig. 5e-h ). Similar effects on γ-H2AX immunofluorescence were observed using either PDS or CX-5461 in NHAs ( Supplementary  Fig. 7a ), and were also seen in both ATRX-knockdown TS 543 and ATRX-mutant 08-0537 GSCs treated with CX-3543, each relative to ATRX-intact counterparts ( Supplementary Fig. 7b ). Moreover, 53BP1-positive DNA damage foci arising with CX-3543 demonstrated extensive colocalization with G4s on confocal microscopy ( Supplementary Fig. 8a-b ), a finding recapitulated by γ-H2AX immunofluorescence in ATRX-deficient NHAs treated with either CX-3543, PDS, or CX-5461, using either BLM or BG4 immunofluorescence to designate G4s ( Supplementary Fig. 8c-d ).
Once again, these effects were reversed following ATRX reexpression ( Fig. 5f , h, and Supplementary Fig. 8b ). Finally, G4 stabilization in ATRX-deficient NHAs bolstered the extent of ChIP enrichment for both BLM and γ-H2AX at putative G4 sites ( Supplementary Fig. 9a-9b ), further demonstrating that causal links between impaired G4 resolution and DNA damage underlie our synthetic lethal approach. Annexin V flow-cytometry confirmed that the heightened sensitivity of ATRX-deficient NHAs to CX-3543 reflected increased apoptosis, and this enhanced cell death followed the kinetics of replication stress pathway activation in both constitutive and inducible isogenic contexts ( Fig. 6a-d) . Analogous experiments in ATRXintact and ATRX-knockdown TS 543 GSCs yielded similar findings ( Supplementary Fig. 10a-b ). In total, these results indicate that chemical stabilization of G4 structures selectively promotes cell death in the ATRX-deficient context, likely by inducing toxic levels of DNA damage. The experimental links, described above, between replication stress, DNA damage, and CX-3543 treatment prompted us to consider whether G4 stabilization might enhance the therapeutic efficacy of established DNA-damaging treatment strategies, particularly in ATRX-deficient context. To evaluate this possibility, we subjected vehicle and CX-3543-treated isogenic NHAs, cultured in soft agar, to increasing doses of either ionizing radiation (IR) or hydroxyurea (HU), assessing viable colonies at 21 days. We found that CX-3543 treatment potentiated the cytotoxicity of both IR and HU, and while these effects were significant for both NHA genotypes, they were particularly strong in the setting of ATRX deficiency (Fig. 6e, f ). Restoring ATRX expression markedly dampened the extent of cytotoxic synergy ( Fig. 6e, f) . Moreover, the ATRX-dependent radiosensitization properties of CX-3543 were recapitulated in TS 543 GSC isogenics, ( Supplementary Fig. 10c ). These findings inform additional therapeutically relevant strategies combining chemical G4 stabilization with well-established treatment modalities in the targeting of ATRX-deficient cancer.
ATRX loss enhances sensitivity to G4 stabilization in vivo.
Having established the increased sensitivity of ATRX-deficient NHAs and GSCs to chemical G4 stabilization in cell culture, we sought to ascertain whether this approach could exhibit a similar degree of efficacy in vivo. To this end, we employed an ATRXmutant, patient-derived GSC line (JHH-273) capable of forming tumors in murine hosts when embedded in the hind flank 43 . Following cellular implantation, we subjected xenografted mice to daily intravenous treatment with either CX-3543 or vehicle and monitored tumor growth over time. We found that CX-3543 dramatically slowed the growth of JHH-273 flank tumors (Fig. 7a,  b and Supplementary Fig. 11a ) and significantly prolonged survival in xenografted mice ( Fig. 7c ). Histopathological examination of CX-3543-treated xenografts revealed cellular depopulation, reduced proliferative activity by Ki-67 immunostaining, and increased γ-H2AX-positive DNA damage foci relative to untreated counterparts, recapitulating in vitro findings (Fig. 7d ). Notably, telomere FISH failed to reveal changes in the level of ALT in residual viable tumor following CX-3543 treatment (Fig. 7d ).
To ascertain whether these effects were specific to the ATRXmutant context, we performed analogous xenograft experiments using ATRX wild-type TS 543 cells. In these studies, we found that CX-3543 treatment had no appreciable effect on either xenograft growth or mouse survival (Fig. 8a, b and Supplementary Fig. 11b ). However, when we subjected these same GSCs to ATRX knockdown, they were rendered sensitive to CX-3543 to an extent similar to that observed for JHH-273 cells (Fig. 8c, d and Supplementary Fig. 11c ). ATRX knockdown also recapitulated histopathological effects on cellular depopulation, proliferative activity, and γ-H2AX-positivity ( Fig. 8e, f) . Consistent with prior reports 19, 22 , ATRX knockdown was not associated with ALT in TS 543 cells ( Fig. 8e, f) . Taken together, these in vivo findings further support the therapeutic potential for chemical G4 stabilization in the selective targeting of ATRXdeficient glioma. b ATRX-mutant GSCs (08-0537) showed significantly increased chromosome breaks by cytogenetic analysis relative to ATRX wild-type GSCs (TS 603). c Quantified chromosome breaks in Atrx-intact and Atrx-KO mNPCs (also Tp53-/-, passage 10). In all cases, 10 sets of chromosomes were quantified. Error bars reflect SEM; P values determined by unpaired, two-tailed t-test
Discussion
As indicated above, loss-of-function mutations in ATRX likely play central pathogenic roles in several distinct tumor variants, including multiple subtypes of incurable glioma. That ATRX itself encodes a chromatin regulatory protein suggests that epigenomic dysfunction underlies, at least in part, the oncogenic sequelae of its inactivation. To this point, we recently demonstrated that ATRX deficiency induces extensive chromatin remodeling and transcriptional shifts in putative glioma cells of origin, driving disease-relevant phenotypes that modulate both cellular motility and differentiation 44 . However, the full impact of ATRX deficiency on tumor initiation and evolution almost certainly includes other molecular mechanisms. The association of ATRX mutation and ALT 17, 22 , for instance, is now extensively described and provides a vehicle to telomerase-independent immortalization in affected cancer cells. Moreover, recent work has linked ALT to the well-characterized genomic instability induced by ATRX deficiency 16, 45 .
The pathogenic consequences of ATRX-dependent genomic instability in the context of cancer are unknown. Abundant prior work has demonstrated links between ATRX deficiency, DNA damage, CNA development, and aneuploidy [18] [19] [20] [21] [22] [23] . Indeed, p53-dependent apoptosis derived from genomic instability in the neuroepithelial progenitor compartment likely underlies the neuronal depopulation, microcephaly, and mental retardation associated with ATR-X syndrome 46 . Replication stress has been extensively implicated as a root cause of genomic instability in ATRX-deficient cells 19, 21, 47 . In addition to activating DNA damage pathway signaling, replication fork stalling and collapse can generate double-strand breaks and defective chromosome condensation during mitosis, both of which are known to drive CNAs and aneuploidy of the kind seen in ATRX-mutant glioma [48] [49] [50] . Recent work strongly supports the notion that the replication stress characterizing ATRX-deficient cells derives, at least in part, from G4 DNA secondary structure 16, [27] [28] [29] . ATRX binds widely at GC-rich genomic sites susceptible to forming G4s 25 , and restored ATRX expression in ATRX-mutant cell lines mitigates G4-associated phenotypes such as ALT 16 . Such data imply that ATRX may serve to protect the genome from unwanted G4 formation and the potentially deleterious consequences of ensuant genomic instability. Our findings support this conjecture by demonstrating, for the first time, that ATRX deficiency potently and reversibly induces G4 formation in isogenic experimental models ranging from transformed astrocytes to patient-derived GSCs. As such, they confirm a novel functionality for a SWI/SNF epigenetic regulator already widely implicated in chromatin remodeling, structure, and organization. That increased G4s were accompanied by replication stress signaling, DNA damage at spatially overlapping sites-as confirmed by both immunofluorescence and ChIP, and diseaserelevant patterns of CNAs in our cell line models provides additional evidence that this pathobiological cascade features in ATRX-mutant neoplasia. Prior computational analysis across multiple tumor types established significant correlations between CNA breakpoints and genomic sites enriched in putative G4-forming sequences 51 , firmly implicating G4s in the process of cancer-associated CNA acquisition. In our NHA models, ATRX knockdown led to a distinct CNA profile over time enriched in alterations over 1 Mb in size. While this pattern did not completely mirror the known CNA signature of ATRX-mutant gliomas 2 , it did recapitulate key elements involving larger, arm-level events. In particular, two CNAs (12p gain and 14q loss) were reminiscent of analogous alterations in human tumors associated with unfavorable prognosis. These data speak directly to the premise that CNA mobilization, driven at least in part by G4-mediated DNA damage, promotes malignant evolution in ATRX-deficient gliomas. As this tumor subtype characteristically progresses slowly over time 52 , such mechanistic insights are consistent with established clinical features.
Due to its sheer prevalence in glioma, ATRX deficiency represents a molecular target of intriguing therapeutic potential. That being said, effective strategies to drug an inactivated epigenetic regulator are not immediately obvious, as they might be in the setting of more conventional, kinase-predominant, ARTICLE oncogenic signaling networks. Given these challenges, leveraging specific vulnerabilities engendered by ATRX loss might offer alternative approaches. In particular, the longstanding association of ATRX deficiency with genomic instability, confirmed in this report, presents a tangible opportunity to explore synthetic lethality paradigms, akin to that of poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of BRCA1-inactivated breast cancer 53 . While the observed level of DNA damage in our ATRXdeficient cell line and tumor models was insufficient to induce apoptosis in isolation, due in part to coincident TP53 inactivation, we hypothesized that its targeted enhancement would overwhelm compensatory mechanisms maintaining cell viability ( Fig. 9 ). Moreover, our identification of G4s as the likely source of ATRXdeficient genomic instability provided a viable approach to therapeutic selectivity. We found that G4 stabilization with multiple distinct agents selectively targeted ATRX-deficient glioma cell lines and tumors, both in vitro and in vivo. That our findings, initially obtained with CX-3543, were recapitulated with CX-5461, and PDS argues that on-target effects dependent on G4 binding were chiefly responsible for observed therapeutic impact. Moreover, cell death in these contexts was temporally associated with DNA damage and replication stress, further supporting impaired G4 resolution as a likely mechanism of action. These results recapitulate recent data showing enhanced sensitivity of ATRX-deficient embryonic stem cells to CX-5461 24 . We cannot completely exclude the possibility that G4-stabilzation exerts some of its cytotoxic effects through the manipulation of ALT. As alluded to above, prior work has functionally linked increased G4s and DNA damage at telomeres with ALT induction in ATRX-deficient cells 16 . Nevertheless, ATRX knockdown was not associated with ALT in our NHA and TS 543 isogenics, consistent with multiple prior reports 19, 20, 22 , and CX-3543 failed to alter the pattern of telomere FISH in ATRX-mutant JHH-273 GSC xenografts. Taken together, these findings strongly suggest that the cytotoxicity of G4 stabilization in the ATRX-deficient context is, at least in large part, mediated by DNA damage genome-wide, not limited to telomeric regions.
We also demonstrated that G4 stabilization dramatically enhanced the effects of IR and HU in ATRX-deficient NHAs, highlighting possibilities for effective synergistic combinations in the clinical setting. Since its introduction almost 40 years ago, IR has remained one of the most important nonsurgical therapeutic modalities employed in the treatment of malignant glioma, with demonstrated efficacy across disease subtypes [54] [55] [56] . Moreover, recent work has shown that ATRX-mutant gliomas in particular exhibit increased sensitivity to DNA-damaging combinations of IR and chemotherapy 57, 58 . This vulnerability may derive in part from increased genomic instability at baseline. Defective non-homologous end joining (NHEJ), documented to arise with ATRX deficiency in preclinical models 20 , may also play a role. Regardless of the precise molecular mechanisms at work, therapeutically potentiating an already effective treatment strategy for glioma represents an underexplored approach with the potential for considerable clinical impact.
Precisely which G4 stabilizer represents the optimal agent for clinical translation remains unclear. Both CX-3543 and CX-5461 have advanced to clinical trials for pancreatic neuroendocrine tumor and BRCA1/2-deficient breast cancer, respectively 40, 42 . However, CX-3543, by report, has limited bioavailability 41 , and no formal blood-brain barrier penetration studies have been released for either. Nevertheless, our findings indicate that the targeted approach of G4 stabilization has considerable therapeutic potential in the treatment of ATRX-deficient glioma, along with other ATRX-mutant cancers. That the strategy is based on a tumor-specific vulnerability arising in association with an easily assessable biomarker should facilitate its clinical application, while also minimizing harmful side effects in treated patients. Moreover, alternative G4-stabilizing agents are currently available for use both as tool compounds and starting points for chemical derivatization 42, 59, 60 .
In summary, we firmly implicate G4 secondary structure as a defining characteristic of ATRX-mutant glioma, one that drives disease-relevant genomic instability and presents opportunities for tangible therapeutic advancement. As such, our work has important implications for both the molecular pathogenesis of ATRX-deficient neoplasia, as well as the development of more effective drugs specifically targeting a palette of deadly tumors.
Methods
Study design. The objective of this study was to determine the impact of ATRX deficiency on G4 formation, DNA damage, and genomic instability in glioma, and assess the potential of chemical G4 stabilization as a therapeutic strategy in ATRX-deficient tumors. This was a controlled, laboratory-based, experimental study using cell line models in culture and in xenografts. ATRX was inactivated by genetic approaches and, in some cases, pharmaceutical agents and/or ionizing radiation were applied. Sample sizes were determined independently for each experiment without formal power calculation. No data was excluded from analysis. Unless otherwise specified, experiments employed three replicates per sample. End points varied by experiment and are described below, in figure legends, or in the Results section. Histopathological and immunohistochemical review of xenografts was conducted by a Neuropathologist (J.T.H.) in a nonblinded fashion. Quantification of G4 and/or γ-H2AX immunostaining in NHAs was blinded.
Antibodies. All commercially available antibodies used in this study, along with their source and application(s), are listed in Supplementary Table 1 . 
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Cell culture and generation of ATRX-deficient cell lines. All cell lines used in this study were tested for mycoplasma contamination every three months at the MSKCC Antibody and Bioresource Core. Parental immortalized normal human astrocytes were a gift from R.O. Peiper (UCSF) 61 . TS 543, TS 603, and 08-0537 are patient-derived GSCs 62-64 maintained in NeuroCult™ NS-A Proliferation media (#05751, Stemcell). 08-0537 was generously provided by Hai Yan (Duke).
ATRX knockdown was achieved by introducing either a modified FUGW vector (a gift from David Baltimore (Addgene plasmid # 14883)) carrying an shRNA expression cassette against ATRX (shATRX1) (see Supplementary Table 2 for shRNA sequences), a TRIPZ TET-inducible vector (Dharmacon) containing a distinct shRNA against ATRX (shATRX2), or a third shRNA against ATRX (sh590) from the TRC shRNA library (Sigma). shATRX1-and shATRX2-positive Proliferation, cell cycle, and apoptosis analyses. Flow-cytometry analyses of proliferation and cell cycle were performed using the BD Pharmingen BrdU Flow Kit (# 559619). Apoptosis assays were performed using the Dead Cell Apoptosis Kit (# V13241, Thermo Fisher) with Propidium Iodide (PI) substituted by DAPI to avoid RFP interference.
In situ visualization of G-quadruplexes, γ-H2AX, 53BP1, and BLM. The 1H6 antibody was a gift from Dr. Peter M. Lansdorp 65 . The BG4 antibody was purchased from Millipore (MABE917). For immunostaining, cells were grown in chamber slides (Nunc Lab-Tek II, cat no. 154526, Thermo Fisher) and synchronized to G0 phase by 24-h serum starvation. The cells were digested with 10 mg/ml proteinase K for 1h at 37°C, followed by fixation (4% paraformaldehyde in PBS for 10 min) and permeabilization (0.5% Tween-20, 0.2% Triton X-100 in PBS, 10 min Cell death Fig. 9 Selectively targeting G4s in the ATRX-deficient context. G4s are normally resolved by both ATRX-dependent and ATRX-independent mechanisms to mitigate DNA damage in cells (a). In the setting of ATRX deficiency, DNA damage increases but its cytotoxic effects are dampened by ATRX-independent G4 resolution, maintaining cellular viability (b). However, concurrent G4 stabilization impairs these salvage pathways (c, d) further enhancing DNA damage and inducing cell death in the ATRX-deficient context NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08905-8 ARTICLE TEL-FISH and metaphase cytogenetic analysis. For cell lines, resuspended cells were incubated with Colcemid (0.1 µg/ml) at 37°C for 45 min, resuspended in 0.075 M KCl and incubated at 37°C for 10 min, followed by fixation in methanol: acetic acid (3:1) solution. TEL-FISH was performed according to standard procedures using a CY3-conjugated, telomere-specific nucleic acid probe: 5'-TTAGGGT TAGGGTTAGGG-3' (Applied Biosystems). For xenograft tissues, tumors were removed and subjected to OCT embedding followed by 5 µm sectioning. Frozen sections were fixed with 4% paraformaldehyde for 10 min. After denaturing at 85°C for 5 min in 10 mM Tris-HCL pH 7.2, 70% formamide, 0.5% blocking solution reagent (Roche), hybridization was performed as described above.
Cell viability and clonogenic assay. For standard viability assays, cells (500/well) were incubated with a serial concentration of CX-3543 (10-300 nM), CX-5461 (2.5-500 nM), or PDS (0.1-20 µM) for 7 days in 96-well plates. Cell viability was then assessed with the CellTiter-Glo Luminescent Assay (Promega) according to manufacturer-recommended procedures. To determine clonogenic ability, NHA or TS 543 cells were seeded at 5000 cells/10-cm dish and incubated with vehicle or 50 nM CX-3543 for 14 days. Cells were fixed with 4% paraformaldehyde and stained with 0.005% crystal violet in PBS, followed by three washes in PBS and two washes in ddH 2 O. For soft agar colony formation assays, 50,000 cells were seeded in 6-well plates containing 1% bottom layer and 0.5% top layer soft agar. Cells were then cultured in growth media with or without 50 nM CX-3543. Radiation dosing of 0, 1, 2, or 4 Gy was immediately applied after plating. The 1.5 ml growth media covering the agar cultures was replenished every week. At day 21, colonies were fixed with 4% paraformaldehyde for 30 min and stained with 0.005% crystal violet in PBS overnight. Stained colonies were then washed extensively in PBS and water, and quantified on a Gelcount colony counter (Oxford Optronix).
SNP arrays. Genomic DNA was isolated from ATRX-deficient NHAs at passages 5 and 15. As controls, genomic DNA from ATRX-intact parental NHAs was derived at the start point (P0), P5, and P15. Extracted DNA was subjected to Affymetrix Genome-Wide Human SNP 6.0 array analysis (cat# 901182, Thermo Fisher) according to the manufacturer's protocol. Preliminary copy number derivation was facilitated by circular binary segmentation 69, 70 to generate CNV segment files with the following information: chromosome, start position, end position, probe number, and segment mean value. For analysis, we focused variations with absolute segment mean value >0.5 for LGG samples and >0.1 for NHA lines. All variations associated with ChrX and ChrY were excluded. CNV length was calculated by using the end position minus the start position. Data were visualized using IGV and GISTIC2.0.
Xenograft experiments. All animal protocols and procedures were performed in the xenograft suite at Memorial Sloan-Kettering Cancer Center (Animal protocol # 07-09-015) in accordance with the ethical and experimental regulations of the Institutional Animal Care and Use Committee (IACUC). JHH-273 samples were kind gifts from Dr. Gregory Riggins at the Johns Hopkins University. Tumor samples were mechanically dissociated and small pieces (0.2 mm 3 ) were embedded into the flanks of nude mice (Taconic Farms). In parallel, ATRX-intact and ATRXdeficient TS 543 cells at exponential growth phase were dissociated with Accutase (#07920, Stemcell), resuspended in Neurocult media, mixed with Matrigel (#356234, Corning) (1:1) and injected into nude mice flanks in a 50 μl mixture containing 5 × 10 6 cells. Mice were randomized to vehicle or CX-3543 (12.5 mg/kg) treatment groups. Drug delivery occurred via intravenous injection once per day, on a 5 day/week schedule until health-related defined end points. Tumor volumes were measured by calipers and calculated using the formula (l × w 2 )/2, where w is width and l is length in mm. For survival experiments, mice were treated until they reached health-related end points (2000 mm 3 tumor volume). For growth curve comparisons, all mice in a study cohort were sacrificed when the first mouse reached the 2000 mm 3 tumor size threshold. An independent cohort was used for Kaplan-Meier analysis. Xenografted tissues were removed, weighted, and split into two parts. One part was snap frozen for TEL-FISH, while the other half was subjected to FFPE processing. five-micrometer FFPE sections were deparaffinized and subjected to antigen retrieval. Sections were blocked for non-specific binding with goat serum for 2 h, followed by staining with Ki67 (5µg/ml, ab15580, Abcam) or γ-H2AX (1:1000, # 05-636, Millipore) antibodies at 4°C overnight. Sections were washed and incubated with secondary antibody. Ki67 staining were counterstained with Hematoxylin, and γ-H2AX staining were counterstained with DAPI.
Statistics. Unless otherwise stated, all results, representing at least three independent experiments, were plotted as mean ± SEM. In general, data were statistically analyzed using unpaired, two-tailed t-tests. Log-rank (Mantel-Cox) test were used to determine the significance of differences in Kaplan-Meier analysis of LGG patients and of hind flank xenograft experiments. Two-way ANOVA was used to compare the growth curves of xenografts and the colony formation assays. P values are represented using * for P < 0.05, ** for P < 0.01, *** for P < 0.001, and **** for P < 0.0001.
Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
